Mechanisms for resistance in AML insights into molecular pathways mediating resistance to venetoclax.

Resistance to therapy continues to pose hurdles in the therapeutic management of acute myeloid leukemia (AML). Although the approval and development of therapies such as venetoclax, was expected to overcome this issue, resistance remains a common occurrence in AML treatment. This review has summarized evidence that will provide insights into acquired mutations that influence response to venetoclax therapy and the utility of novel combination approaches in improving outcomes.